• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

侵袭性垂体肿瘤和癌:同一枚硬币的两面?

Aggressive pituitary tumours and carcinomas: two sides of the same coin?

机构信息

Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France.

Endocrinology, Skåne University Hospital, Malmo, Sweden.

出版信息

Eur J Endocrinol. 2018 Jun;178(6):C7-C9. doi: 10.1530/EJE-18-0250. Epub 2018 Mar 27.

DOI:10.1530/EJE-18-0250
PMID:29588294
Abstract

The European Society of Endocrinology (ESE) survey reported on the largest cohort of 125 aggressive pituitary tumours (APT) and 40 pituitary carcinomas (PC). Whilst the survey focused on treatment effectiveness, all pathological data were not explored in detail. Here, we comment on some interesting pathological findings, notably the difference between APT and PC.

摘要

欧洲内分泌学会(ESE)的调查报道了最大的 125 例侵袭性垂体肿瘤(APT)和 40 例垂体癌(PC)队列。虽然该调查侧重于治疗效果,但并未详细探讨所有病理数据。在这里,我们对一些有趣的病理发现发表评论,特别是 APT 和 PC 之间的差异。

相似文献

1
Aggressive pituitary tumours and carcinomas: two sides of the same coin?侵袭性垂体肿瘤和癌:同一枚硬币的两面?
Eur J Endocrinol. 2018 Jun;178(6):C7-C9. doi: 10.1530/EJE-18-0250. Epub 2018 Mar 27.
2
Aggressive Pituitary Adenomas and Carcinomas.侵袭性垂体腺瘤和腺癌。
Endocrinol Metab Clin North Am. 2020 Sep;49(3):505-515. doi: 10.1016/j.ecl.2020.05.008. Epub 2020 Jul 8.
3
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.促皮质素细胞侵袭性垂体肿瘤和癌常携带 ATRX 突变。
J Clin Endocrinol Metab. 2021 Mar 25;106(4):1183-1194. doi: 10.1210/clinem/dgaa749.
4
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.侵袭性垂体腺瘤和腺癌是否为同一枚硬币的两面?病理学家解答临床医生的疑问。
Rev Endocr Metab Disord. 2020 Jun;21(2):243-251. doi: 10.1007/s11154-020-09562-9.
5
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.欧洲内分泌学会侵袭性垂体肿瘤和癌管理临床实践指南
Eur J Endocrinol. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18.
6
The pathogenesis of pituitary tumors.垂体肿瘤的发病机制。
Annu Rev Pathol. 2009;4:97-126. doi: 10.1146/annurev.pathol.4.110807.092259.
7
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.侵袭性垂体肿瘤和癌,171 例患者的特征和治疗。
Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.
8
The epidemiology of aggressive pituitary tumors (and its challenges).侵袭性垂体瘤的流行病学(及其挑战)。
Rev Endocr Metab Disord. 2020 Jun;21(2):209-212. doi: 10.1007/s11154-020-09556-7.
9
Multiple intracranial tumors: coexistence of a glioblastoma and null cell pituitary adenoma within the same patient.
Clin Neurol Neurosurg. 2014 May;120:120-3. doi: 10.1016/j.clineuro.2014.03.002. Epub 2014 Mar 13.
10
The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.垂体腺瘤分子登记处(REMAH):西班牙内分泌学对个性化医学和转化研究未来的一次押注。
Endocrinol Nutr. 2016 Jun-Jul;63(6):274-84. doi: 10.1016/j.endonu.2016.03.001. Epub 2016 Apr 16.

引用本文的文献

1
Clinical features of pituitary carcinoma: analysis based on a case report and literature review.垂体癌的临床特征:基于病例报告和文献复习的分析。
Front Endocrinol (Lausanne). 2024 Oct 31;15:1440247. doi: 10.3389/fendo.2024.1440247. eCollection 2024.
2
High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience.垂体神经内分泌肿瘤(PitNENs)的高级别进展、肉瘤样转化和/或转移:加州大学旧金山分校的经验
Endocr Pathol. 2024 Dec;35(4):338-348. doi: 10.1007/s12022-024-09829-w. Epub 2024 Oct 10.
3
The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.
《2022年世界卫生组织垂体肿瘤分类:侵袭性和转移性垂体神经内分泌肿瘤的最新进展》
Brain Pathol. 2025 Jan;35(1):e13302. doi: 10.1111/bpa.13302. Epub 2024 Sep 1.
4
Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.儿童和青少年垂体腺瘤诊断和管理的共识指南:第 1 部分,一般建议。
Nat Rev Endocrinol. 2024 May;20(5):278-289. doi: 10.1038/s41574-023-00948-8. Epub 2024 Feb 9.
5
Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.肿瘤微环境在垂体神经内分泌肿瘤中的作用:分类、诊断和治疗的新方法
Cancers (Basel). 2023 Nov 6;15(21):5301. doi: 10.3390/cancers15215301.
6
An update on, and genetics of refractory adenomas of childhood.儿童难治性腺瘤的最新进展及遗传学
Pituitary. 2023 Jun;26(3):281-287. doi: 10.1007/s11102-023-01327-2. Epub 2023 Jun 15.
7
Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.基于常规 MRI 的形态和纹理分析对垂体腺瘤侵袭性的术前预测。
Eur Radiol. 2023 May;33(5):3312-3321. doi: 10.1007/s00330-023-09412-7. Epub 2023 Feb 4.
8
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling.PIT1 阳性垂体腺瘤的单细胞测序突出了 IFN-γ 诱导的肿瘤相关成纤维细胞重塑介导的促肿瘤微环境。
Br J Cancer. 2023 Apr;128(6):1117-1133. doi: 10.1038/s41416-022-02126-5. Epub 2023 Jan 11.
9
Phosphorylation of β-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours.β-连环蛋白丝氨酸 552 磷酸化与无功能垂体神经内分泌肿瘤的侵袭和复发相关。
Acta Neuropathol Commun. 2022 Sep 16;10(1):138. doi: 10.1186/s40478-022-01441-5.
10
Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.侵袭性垂体肿瘤和癌,171 例患者的特征和治疗。
Eur J Endocrinol. 2022 Sep 19;187(4):593-605. doi: 10.1530/EJE-22-0440. Print 2022 Oct 1.